Provir antiviral data

SHMN presented results of a challenge study in which healthy adults were exposed to the virus, which most often produces disease in children. The low level of infection in adults and the small number of volunteers in the trial precluded statistical analysis. But the study conducted at the University of Rochester further demonstrated the product's safety, researchers said at the S.G. Warburg Emerging Pharmaceuticals Conference in London.

Of the 32 volunteers enrolled, 11 received 2 mg/kg daily, 11 received 10 mg/ kg, and 10 got placebo. A previous Phase I trial of Provir demonstrated safety in more than 90 patients. ...